Format

Send to

Choose Destination
Curr Neurol Neurosci Rep. 2015 Mar;15(3):2. doi: 10.1007/s11910-015-0524-6.

Invasive meningococcal disease in the 21st century—an update for the clinician.

Author information

1
Department of Pediatrics and Child Health, College of Medicine, University of Manitoba, Room 530B, Basic Medical Sciences Building, 745 Bannatyne Avenue, Winnipeg, MB, Canada, R3E 0J9, rdwilow@exchange.hsc.mb.ca.

Abstract

Neisseria meningitidis is a gram-negative diplococcus, for which humans are the only reservoir. While colonization is common, invasive meningococcal disease in the form of meningitis or bacteremia can be devastating and potentially fatal. Certain populations are at higher risk for disease including infants, adolescents, those with asplenia or complement deficiencies, and potentially those with human immunodeficiency virus (HIV) infection. Use of conjugate meningococcal vaccines has impacted disease epidemiology in both high- and low-income countries. Outbreaks of serogroup B disease at university campuses have drawn further attention to the recent development of a novel serogroup B vaccine now approved in many countries. This review covers key aspects of the pathogenesis and management of meningococcal disease, as well as the very recent developments in disease epidemiology, outbreaks, and the evolution of meningococcal immunizations.

PMID:
25637287
DOI:
10.1007/s11910-015-0524-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center